All filters
E-Posters
Dual Therapy Including Dolutegravir Plus Boosted-Darunavir Ensures High Rate Of Virological Control And Rare Resistance Selection At Failure In Heavily Treatment Experienced PLWH
D. Armenia
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Real-World Effectiveness Of Elbasvir/Grazoprevir In The Treatment Of Patients With Hepatitis C Virus Genotype 1A Infection In Norway
R. A. Leiva
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Dual Therapy With Dolutegravir Plus Lamivudine In Virologically Suppressed Patients
C. I. Simoes Valente
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
HIV A1 Or B Do Not Differentially Impact Cabotegravir In Vitro Potency Or Durability
J. Jeffrey
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Molecular Epidemiology Of The HIV-1 Infection In Cyprus (2017-2019): A Polyphyletic Infection With An Increasing Prevalence Of Drug Resistance
L. Kostrikis
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
HIV Evolution In Patients Initiating Antiretroviral Therapy During Primary Infection
B. Abdi
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
A Changing Of HIV-1 Genetic Diversity In Russia During The Last Two Decades: Increase Of The Recombinants Prevalence
A. Antonova
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Unexpected Rising In The Circulation Of Complex HBV Variants Enriched Of HBsAg Vaccine-Escape Mutations In HBV Genotype-D: Potential Impact On HBsAg Detection/Quantification And Vaccination Strategies
M. Alkhatib
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Residual Phenotypic Susceptibility To Second Generation Nnrti In Multidrug Resistant HIV-1 From The Prestigio Registry
F. Saladini
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Susceptibility To HIV-1 Integrase Inhibitors In HIV-1 Sub-Subtype A6 Isolates
A. Giannini
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Two-Drug Regimen (2DR) For Initial HIV Treatment? – Lessons Learned From 20 Years Resina Cohort
N. Lübke
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Transmitted Drug Resistance To Integrase Based First-Line HIV Antiretroviral Treatment In The MeditRes HIV Collaboration
F. GarcÃa
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Dynamics Of HIV-1 Transmission Clusters In North And Central Italy Over The Years 2012-2019
R. Scutari
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Exploring Molecular Characteristics And Evolutionary Dynamics Of The HIV-1 Epidemic In Montenegro Through Phylogenetic Analyses
S. Dragas
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Prevalence And Spatiotemporal Dynamics Of The HIV-1 Circulating Recombinant Form 03_AB (CRF03_AB) In The Former Soviet Union
E. Ozhmegova
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Short- And Long-Term Direct Medical Costs Of Late And Very Late HIV Presentation
L. Versteegh
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Cabotegravir + Rilpivirine Every 2 Months Is Noninferior To Monthly: ATLAS-2M Study
P. Benn
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Treatment Outcome Among People Living With Hiv Starting First-Line Rapid Or GRT Guided ART From 2015 To 2018
A. De Vito
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Evaluation Of HIV-1 Tropism In Multidrug-Resistant cART Failing Patients
Y. Bouba
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Assessment Of Genotypic Patterns Associated With HIV-1 Sensitivity To Ibalizumab
H. Jullien
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
DTG+3TC vs DTG+TDF/FTC (GEMINI1&2): Confirmed Virologic Withdrawals Through Week 96
J. Van Wyk
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Role Of Analitical Treatment Interruption On HIV Peripheral Reservoir Diversification
C. Alteri
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
In Vitro Activity Of Islatravir Against HIV-1 Mutants Harboring Multiple NRTI Resistance Mutations
F. Giammarino
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Similar Levels Of HIV-Dna And Residual Viremia Are Found In Virologically Suppressed Individuals Who Continue A Two-Drug Regimen With Dolutegravir Plus One Reverse Transcriptase Inhibitor Or Switch To Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafen
M. M. Santoro
Presented at:
European Meeting on HIV & Hepatitis 2020